|
|
|
| Value of Serum NT-proBNP,H-FABP and VEGF-B in Predicting Coronary Heart Disease and Cardiac Function |
| JING Xiao, YANG Miao-ying |
| Department of Laboratory Medicine,Xi'an High-tech Hospital,Xi'an Shaanxi 710075 |
|
|
|
|
Abstract 【Objective】 To study the effects of changes in NT-proBNP,H-FABP,and VEGF-B levels on cardiac function in patients with coronary heart disease.【Methods】 Eighty-seven patients with coronary heart disease were selected as the observation group,and 80 healthy subjects were used as the control group.NT-proBNP,H-FABP,VEGF-B,left ventricular end-diastolic volume (LVEDV),left ventricular end-systolic volume (LVESV),left ventricular ejection fraction (LVEF),cardiac output,volume (CO) and cardiac index (CI) were measured before and after treatment in the observation group; And they were compared with the control group.The NYHA cardiac function grading before and after treatment in the observation group were analyzed.【Results】 The levels of NT-proBNP,H-FABP,and VEGF-B in the control group were significantly lower than those in the observation group both before treatment and after treatment.The NT-proBNP,H-FABP and VEGF-B levels in the observation group after treatment were significantly lower than those before treatment (P<0.05).The LVEDV,LVESV,and LVEF levels in the control group were significantly higher than those before treatment and after treatment in the observation group.After treatment,LVEDV,LVESV,and LVEF levels of the observation group were significantly higher than those before treatment.The CO and CI of the control group were significantly higher than those of the observation group.The CO of the observation group after treatment was significantly higher than that before treatment (P<0.05).There were no significant differences in CO and CI between the control group and the observation group (P>0.05).The cardiac function of the observation group after treatment was significantly higher than that before treatment; And the difference was statistically significant (P<0.05).【Conclusion】 Detection of changes in NT-proBNP,H-FABP,and VEGF-B levels can predict the severity of patients with coronary heart disease.
|
|
Received: 08 August 2022
|
|
|
|
|
|
[1] 常久魁,刘晓荣,郑建辉,等.NT-proBNP与H-FABP在高血压性脑出血患者近期预后的相关性分析[J].现代生物医学进展,2016,16(16):3154-3157.
[2] 曾凯辉.右美托咪定复合七氟醚对冠心病患者非心脏手术后心肌损伤及氧化应激反应的影响[J].海南医学院学报,2017,23(18):2468-2471.
[3] 郑志君,王晓蕊,邱涛,等.参附注射液对老年慢性心衰患者血清NT-proBNP、H-FABP及CRP水平的影响[J].现代生物医学进展,2016,16(16):3134-3137.
[4] 柳彩侠,卜林,孙东.慢性心肾综合征患者外周血TnI、NT-proBNP、H-FABP及MYO水平观察[J].山东医药,2017,57(7):27-30.
[5] ANNELIEE F,ANNIKA M,ISOLDE P,et al.Reducing VEGF-B signaling ameliorates renal lipotoxicity and protects against diabetic kidney disease[J].Cell Metab,2017,25(3):713-726.
[6] 中华医学会心血管病学分会预防学组.冠心病患者运动治疗中国专家共识[J].中华心血管病杂志,2015,43(7):575-588.
[7] 马一铭,李丽,郭涛,等.体外心脏震波对冠心病患者外周血内皮祖细胞、血管内皮生长因子和IL -8的影响及疗效评价[J].医学研究生学报,2017,30(1):42-47.
[8] 邵博一,邹建刚.白细胞水平及心型脂肪酸结合蛋白水平与冠心病心力衰竭患者心功能的相关性分析[J].医学临床研究,2016,33(10):2064-2066.
[9] JANG C,OH S F,WADA S,et al.A branched-chain amino acid metabolite drives vascular fatty acid transport and causes insulin resistance.[J].Nat Med,2016,22(4):421-426.
[10] 黄兴清.抗阻运动在冠心病心力衰竭治疗中的应用研究[J].中国循证心血管医学杂志,2017,9(2):203-205.
[11] BJURMAN C,PETZOLD M,VENGE P,et al.High-sensitive cardiac troponin,NT-proBNP,hFABP and copeptin levels in relation to glomerular filtration rates and a medical record of cardiovascular disease[J].Clin Biochem,2015,48(4-5):302-307.
[12] 杨琴,张建起,张梅,等.STEMI患者急诊PCI术前H-FABP水平与预后的关系[J].天津医药,2017,45(11):1157-1161.
[13] 陈萍,贾彦军,李杨,等.不同糖耐量人群血浆血管内皮生长因子-B水平与胰岛素抵抗的相关性研究[J].中国糖尿病杂志,2017,25(1):25-29.
[14] 黄兴清.抗阻运动在冠心病心力衰竭治疗中的应用研究[J].中国循证心血管医学杂志,2017,9(2):203-205.
[15] 陶鹏辉.hs-CRP、CTnⅠ、H-FABP及VEGF-B对急性心肌梗死早期诊断的临床价值[J].实验与检验医学,2017,35(4):585-588. |
|
|
|
2023, Vol. 40 
